Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MukoCell tissue-engineered oral mucosa vs native oral mucosa graft urethroplasty in male urethral stricture
2018-003532-71Phase 3Active
- Sponsor
- MukoCell GmbH
- Start
- Mar 2019
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 3 trial of MukoCell in Urethral stenosis (2 arms), sponsored by MukoCell GmbH. Primary endpoint: Recurrence rate (treatment failure rate) at 12 months. Started Mar 2019; status: active.
02
Drugs
MukoCell
03
Conditions
Urethral stenosis
Beyond the preview
Go deeper on 2018-003532-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003532-71.